Month: March 2016

• March 31, 2016
• Imaging & mpMRI

An Update on the Current Role for Prostate Multiparametric MRI

A prominent urologist wrote an articulate article on how the U.S. Preventive Services Task Force made a recommendation against broad PSA screening based on an oversimplification of a complex issue. He made an eloquent declaration on several ways in which urologists are “embracing strategies to preserve, or even further decrease, prostate cancer mortality while minimizing keep reading

• March 28, 2016
• Active Surveillance
• Imaging & mpMRI

Multiparametric MRI Adds Value to Surveillance Monitoring

It’s always reassuring to receive affirmation, especially when offering a leading edge medical program to prostate cancer patients. Such was the case for us at the Sperling Prostate Center with the December, 2015 publication of a UCLA Medical Center study on the value-added of multiparametric MRI during Active Surveillance (AS). The authoritative Journal of Urology keep reading

• March 6, 2016
• Other Treatments

Concern Regarding Radiation Overuse

Here’s a little quiz: Which whole gland therapy for prostate cancer has the highest risk of recurrence? Radical prostatectomy Radiation therapy Cryotherapy of the whole gland HIFU of the whole gland If you answered radiation, you are correct. According to a recent article, the rate of prostate cancer coming back after conventional external beam radiation keep reading

• March 1, 2016
• Active Surveillance

The Right Way to do Active Surveillance

We know that the use of Active Surveillance (AS) as a way to hold off on prostate cancer (PCa) treatment is on the rise. Concerns about overtreatment, such as doing a prostatectomy on a patient who only has a small Gleason 3+3 tumor, stem from two recognized realities: Insignificant PCa may be slow-growing (indolent) and keep reading